Kenneth W Merrell1, Michael G Haddock1, J Fernando Quevedo2, William S Harmsen3, Michael L Kendrick4, Robert C Miller1, Christopher L Hallemeier5. 1. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 2. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Department of General Surgery, Mayo Clinic, Rochester, Minnesota. 5. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: hallemeier.christopher@mayo.edu.
Abstract
PURPOSE: Resection of exocrine pancreatic cancer is necessary for cure, but locoregional and distant relapse is common. We evaluated our institutional experience to better understand risk factors for locoregional failure (LRF) and its impact on overall survival (OS). METHODS AND MATERIALS: We reviewed 1051 consecutive patients with nonmetastatic exocrine pancreatic cancer who underwent resection at our institution between March 1987 and January 2011. Among them, 458 had adequate follow-up and evaluation for study inclusion. All patients received adjuvant chemotherapy (n=80 [17.5%]) or chemoradiation therapy (n=378 [82.5%]). Chemotherapy and chemoradiation therapy most frequently consisted of 6 cycles of gemcitabine and 50.4 Gy in 28 fractions with concurrent 5-fluorouracil, respectively. Locoregional control (LRC) and OS were estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed with Cox proportional hazards regression models incorporating propensity score. RESULTS: Median patient age was 64.5 years (range: 29-88 years). Median follow-up for living patients was 84 months (range: 6-300 months). Extent of resection was R0 (83.8%) or R1 (16.2%). Overall crude incidence of LRF was 17% (n=79). The 5-year LRC for patients with and without radiation therapy was 80% and 68%, respectively (P=.003; hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.28-0.76). Multivariate analysis, incorporating propensity score, indicated radiation therapy (P<.0001; HR: 0.23; 95% CI: 0.12-0.42) and positive lymph node ratio of ≥0.2 (P=.02; HR: 1.78; 95% CI: 1.10-2.9) were associated with LRC. In addition, LRF was associated with worse OS (P<.0001; HR: 5.0; 95% CI: 3.9-6.3). CONCLUSIONS: In our analysis of 458 patients with resected pancreatic cancer, positive lymph node ratio of ≥0.2 and no adjuvant chemoradiation therapy were associated with increased LRF risk. LRF was associated with poor OS. Radiation therapy should be considered as adjuvant locoregional treatment following pancreatic cancer resection.
PURPOSE: Resection of exocrine pancreatic cancer is necessary for cure, but locoregional and distant relapse is common. We evaluated our institutional experience to better understand risk factors for locoregional failure (LRF) and its impact on overall survival (OS). METHODS AND MATERIALS: We reviewed 1051 consecutive patients with nonmetastatic exocrine pancreatic cancer who underwent resection at our institution between March 1987 and January 2011. Among them, 458 had adequate follow-up and evaluation for study inclusion. All patients received adjuvant chemotherapy (n=80 [17.5%]) or chemoradiation therapy (n=378 [82.5%]). Chemotherapy and chemoradiation therapy most frequently consisted of 6 cycles of gemcitabine and 50.4 Gy in 28 fractions with concurrent 5-fluorouracil, respectively. Locoregional control (LRC) and OS were estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed with Cox proportional hazards regression models incorporating propensity score. RESULTS: Median patient age was 64.5 years (range: 29-88 years). Median follow-up for living patients was 84 months (range: 6-300 months). Extent of resection was R0 (83.8%) or R1 (16.2%). Overall crude incidence of LRF was 17% (n=79). The 5-year LRC for patients with and without radiation therapy was 80% and 68%, respectively (P=.003; hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.28-0.76). Multivariate analysis, incorporating propensity score, indicated radiation therapy (P<.0001; HR: 0.23; 95% CI: 0.12-0.42) and positive lymph node ratio of ≥0.2 (P=.02; HR: 1.78; 95% CI: 1.10-2.9) were associated with LRC. In addition, LRF was associated with worse OS (P<.0001; HR: 5.0; 95% CI: 3.9-6.3). CONCLUSIONS: In our analysis of 458 patients with resected pancreatic cancer, positive lymph node ratio of ≥0.2 and no adjuvant chemoradiation therapy were associated with increased LRF risk. LRF was associated with poor OS. Radiation therapy should be considered as adjuvant locoregional treatment following pancreatic cancer resection.
Authors: Hunter C Gits; Amy H Tang; William S Harmsen; William R Bamlet; Rondell P Graham; Gloria M Petersen; Thomas C Smyrk; Amit Mahipal; Roman O Kowalchuk; Jonathan B Ashman; William G Rule; Dawn Owen; Michelle A Neben Wittich; Robert R McWilliams; Thorvardur Halfdanarson; Wen Wee Ma; Terence T Sio; Sean P Cleary; Mark J Truty; Michael G Haddock; Christopher L Hallemeier; Kenneth W Merrell Journal: J Gastrointest Oncol Date: 2021-10
Authors: Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams Journal: Am J Clin Oncol Date: 2018-12 Impact factor: 2.339
Authors: Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2020-05-25 Impact factor: 5.344
Authors: Ross A Abrams; Kathryn A Winter; Howard Safran; Karyn A Goodman; William F Regine; Adam C Berger; Michael T Gillin; Philip A Philip; Andrew M Lowy; Abraham Wu; Thomas A DiPetrillo; Benjamin W Corn; Samantha A Seaward; Michael G Haddock; Suisui Song; Yixing Jiang; Barbara J Fisher; Alan W Katz; Sharmila Mehta; Christopher G Willett; Christopher H Crane Journal: Am J Clin Oncol Date: 2020-03 Impact factor: 2.787
Authors: Patrick Wald; X Shawn Liu; Cory Pettit; Mary Dillhoff; Andrei Manilchuk; Carl Schmidt; Evan Wuthrick; Wei Chen; Terence M Williams Journal: Oncotarget Date: 2017-08-16
Authors: Adam R Wolfe; Patrick Wald; Amy Webb; Nikhil Sebastian; Steve Walston; Ryan Robb; Wei Chen; Marall Vedaie; Mary Dillhoff; Wendy L Frankel; Wooil Kwon; Jin-Young Jang; Terence M Williams Journal: Oncotarget Date: 2020-03-10
Authors: Roman O Kowalchuk; Scott C Lester; Rondell P Graham; William S Harmsen; Lizhi Zhang; Thorvardur R Halfdanarson; Rory L Smoot; Hunter C Gits; Wen Wee Ma; Dawn Owen; Amit Mahipal; Robert C Miller; Michelle A Neben Wittich; Sean P Cleary; Robert R McWilliams; Michael G Haddock; Christopher L Hallemeier; Mark J Truty; Kenneth W Merrell Journal: Front Oncol Date: 2021-05-11 Impact factor: 6.244